Skip to content

Home
About Us
Clinical Trials
Science & Technology
Pipeline
Investor Relations
Resources
Patient Resources
Contact

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

December 9, 2025

Share this post

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links

About Us
Clinical Trials
Investor Relations
Patient Resources
Pipeline
Resources
Science & Technology

About Us
Clinical Trials
Investor Relations
Patient Resources
Pipeline
Resources
Science & Technology

follow us

Linkedin Youtube Twitter

Contact Us

5850 San Felipe St., Suite 500 Houston, TX 77057 USA

+1 800-587-8170

© 2026 Coya Therapeutics, Inc. All rights reserved.

Privacy Policy
Terms & Conditions

Biotech Website Design